Preparation of the albumin nanoparticle system loaded with both paclitaxel and sorafenib and its evaluation in-vitro and in-vivo

Journal of Microencapsulation

Volumn 28, Issue 6, 2011, Pages 528-536

  Zhang, Jin Yang ^a   He, Bing ^a   Qu, Wei ^a   Cui, Zheng ^a   Wang, Yi Bo ^a   Zhang, Hua ^a   Wang, Jian Cheng ^a   Zhang, Qiang ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Albumin nanoparticles; Antitumour effect; Combination therapy; Paclitaxel; Sorafenib; Toxicity

Indexed keywords

ALBUMIN; ALBUMIN NANOPARTICLE; NANOPARTICLE; PACLITAXEL; SORAFENIB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CONTROLLED STUDY; DRUG EFFICACY; DRUG RELEASE; DRUG SYNTHESIS; ENCAPSULATION; FEMALE; FREEZE DRYING; HEMOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MORPHOLOGY; MOUSE; NONHUMAN; PARTICLE SIZE; TOXICITY; TUMOR MODEL; ZETA POTENTIAL;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CATTLE; CELL LINE, TUMOR; DRUG CARRIERS; FEMALE; HEMOLYSIS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; NANOPARTICLES; NEOPLASMS; PACLITAXEL; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; SERUM ALBUMIN, BOVINE;

EID: 80051756809     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652048.2011.590614     Document Type: Article

References (31)

1. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest, 2003;111:1287-95. (Pubitemid 36554699)
2. Carter CA, Chen C, Brink C, Vincent P, Maxuitenko YY, Gilbert KS, Waud WR, Zhang X. Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma. Canc Chemother Pharmacol, 2007;59:183-95. (Pubitemid 44885148)
3. Chi LM, Wu WG. Mechanism of hemolysis of red blood cell mediated by ethanol. Biochim Biophys Acta (BBA)-Biomembranes, 1991;1062:46-50.
4. Cristina RA. Pharmacogenomics of paclitaxel. Pharmacogenomics, 2010; 11:621-3.
5. Davidson NG. Single-agent paclitaxel as first-line treatment of metastatic breast cancer: The British experience. Semin Oncol, 1996;23:6-10. (Pubitemid 26362178)
6. Desai NP, Tao C, Yang A, Louie L, Zheng TL, Yao ZW, Soon-Shiong P, Magdassi S. 1998. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof. WO98/14174.
7. Emmenegger U, Kerbel RS. Cancer: Chemotherapy counteracted. Nature, 2010;468: 637-8.
8. Ferrara N. VEGF and the quest for tumor angiogenesis factors. Nat Rev Cancer, 2002;2:795-803. (Pubitemid 37328914)
9. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med, 1971;285:1182-6.
10. Folkman J. Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med, 1995;333:1757-63.
11. Folkman J. Angiogenesis and apoptosis. Semin Cancer Biol, 2003;13: 159-67. (Pubitemid 36315933)
12. Guo XD, Tan JP, Kim SH, Zhang LJ, Zhang Y, Hedrick JL, Yang YY, Qian Y. Computational studies on self-assembled paclitaxel structures: Templates for hierarchical block copolymer assemblies and sustained drug release. Biomaterials, 2009;30:6556-63.
13. Haglund C, Aleskog A, Hakansson LD, Höglund M, Jacobsson S, Larsson R, Lindhagen E. The FMCA-GM assays, high throughput non-clonogenic alternatives to CFU-GM in preclinical hematotoxicity testing. Toxicol Lett, 2010;194:102-7.
14. Kolch W. Meaningful relationships: The regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J, 2000;351(Pt 2): 289-305.
15. Kratz F. Albumin as a drug carrier design of prodrugs, drug conjugates and nanoparticles. Journal of Control Release, 2008;132:171-83.
16. Langer CJ, McAleer CA, Bonjo CA, Litwin S, Millenson M, Kosierowski R, Blankstein K, Alexander R, Ozols RF. Paclitaxel by 1-h infusion in combination with carboplatin in advanced non-small cell lung carcinoma (NSCLC). Eur J Cancer, 2000;36:183-93. (Pubitemid 30102194)
17. Micha JP, Goldstein BH, Birk CL, Rettenmaier MA, Brown III JV. Abraxane in the treatment of ovarian cancer: The absence of hypersensitivity reactions. Gynecol Oncol, 2006;100(2):437-8. (Pubitemid 43075284)
18. Ng R, Chen EX. Sorafenib (BAY 43-9006): Review of clinical development. Curr Clin Pharmacol, 2006;1:223-8.
19. Ojima I. Guided molecular missiles for tumor-targeting chemotherapy-case studies using the second-generation taxoids as warheads. Acc Chem Res, 2008;41:108-19.
20. Panchagnula R. Pharmaceutical aspects of paclitaxel. Int J Pharm, 1998;172:1-15. (Pubitemid 28430240)
21. Pennacchietti S, Michieli P, Galluzzo M, Giordano S, Comoglio PM. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell, 2003;3:347-61. (Pubitemid 38340304)
22. Rosen L. Antiangiogenic strategies and agents in clinical trials. Oncologist, 2000;1:20-7. (Pubitemid 30225453)
23. Safavy A, Raisch KP, Khazaeli MB, Buchsbaum DJ, Bonner JA. Paclitaxel derivatives for targeted therapy of cancer: Toward the development of smart taxanes. J Med Chem, 1999;42:4919-24.
24. Singla AK, Garg A, Aggarwal D. Paclitaxel and its formulation. Int J Pharm, 2002;235:179-92.
25. Steeg PS. Angiogenesis inhibitors: Motivators of metastasis? Nat Med, 2003;9:822-3. (Pubitemid 36889916)
26. Thakkar H, Sharma RK, Mishra AK, Chuttani K, Murthy RR. Albumin microspheres as carriers for the antiarthritic drug celecoxib. AAPS Pharm Sci Tech, 2005;6:E65-73. (Pubitemid 41630999)
27. Tyulina OV, Huentelman MJ, Prokopieva VD, Boldyrev AA, Johnson P. Dose ethanol metabolism affect erythrocyte hemolysis? Biochim Biophys Acta (BBA)-Biomembranes, 2000;1535:69-77.
28. Wang YB, Wang JC, Meng M, Zhang H, Zhang Q. Preparation and evaluation of docetaxel-loaded albumin nanoparticles for intravenous administration. J Chin Pharm Sci, 2010;19:214-22.
29. Wilhelm SM, Carter C, Tang L. BAY 4329006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res, 2004;64:7099-109. (Pubitemid 39331023)
30. Wood WC, Budman DR, Korzun AH, Cooper MR, Younger J, Hart RD, Moore A, Ellerton JA, Norton L, Ferree CR. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med, 1994;330:1253-9.
31. World Health Organization. 2008. Are the Number of Cancer Cases Increasing or Decreasing in the World? WHO [Online] Available at: http://www.who.int/features/qa/15/en/index.html. Accessed July 2010.